Henlius’ Rituximab Results Bolster RA Ambitions In China

Reports Positive Phase III Data At National Congress Of Chinese Rheumatology

 
• By Dave Wallace

Shanghai Henlius Biotech has taken its groundbreaking Chinese rituximab biosimilar a step closer to securing a key rheumatoid arthritis indication.

China Flag Thumbs Up
Henlius is hoping to secure Chinese approval for the RA indication • Source: Alamy

More from Biosimilars

More from Products